Theravance Biopharma (TBPH) News Today $8.28 +0.04 (+0.49%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC lowered its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 90.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,853 shares of the biopharmOctober 26, 2024 | marketbeat.comZacks Research Issues Positive Estimate for TBPH EarningsOctober 25, 2024 | americanbankingnews.comTheravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024October 24, 2024 | prnewswire.comQ4 EPS Forecast for Theravance Biopharma Raised by AnalystOctober 24, 2024 | americanbankingnews.comWhat is Zacks Research's Forecast for TBPH Q3 Earnings?Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Investment analysts at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Theravance Biopharma in a research note issued to investors on Monday, October 21st. Zacks Research analyst R. Department now anticipates tOctober 23, 2024 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Average PT from AnalystsOctober 23, 2024 | americanbankingnews.comWhat is Zacks Research's Estimate for TBPH Q4 Earnings?Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Equities research analysts at Zacks Research upped their Q4 2025 earnings estimates for shares of Theravance Biopharma in a research note issued to investors on Monday, October 21st. Zacks Research analyst R. Department now forecasts that tOctober 22, 2024 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of "Hold" by AnalystsTheravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) has earned a consensus rating of "Hold" from the five analysts that are currently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and two have assigned a buy recommeOctober 20, 2024 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving Average - Here's What HappenedTheravance Biopharma (NASDAQ:TBPH) Share Price Crosses Below 200 Day Moving Average - Time to Sell?October 19, 2024 | marketbeat.comTheravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary DiseaseOctober 18, 2024 | prnewswire.comDimensional Fund Advisors LP Purchases 91,679 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)Dimensional Fund Advisors LP raised its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 38.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 330,181 shares of the biopharmaceuticalOctober 11, 2024 | marketbeat.comSquarepoint Ops LLC Makes New $986,000 Investment in Theravance Biopharma, Inc. (NASDAQ:TBPH)Squarepoint Ops LLC bought a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 116,256 shares of the biopharmaceutical company's stock, valued at approximately $986,000. Squarepoint OpOctober 7, 2024 | marketbeat.comBank of Montreal Can Raises Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Bank of Montreal Can lifted its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 141.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 160,138 shares of the biopharmaceutical company's stock afOctober 6, 2024 | marketbeat.comMarshall Wace LLP Grows Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Marshall Wace LLP boosted its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 83.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 297,499 shares of the biopharmaceutical company's stock afOctober 4, 2024 | marketbeat.comInvest Alongside Wall Street Legend Seth Klarman: 2 New Stocks He Bought and 1 He DumpedSeptember 29, 2024 | 247wallst.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Hold" from BrokeragesShares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five brokerages that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and two have given a buySeptember 25, 2024 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Stake Lessened by Baupost Group LLC MABaupost Group LLC MA decreased its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 36.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,200,021September 21, 2024 | marketbeat.comBuy Rating Affirmed for Theravance Biopharma on Yupelri Growth and Ampreloxetine Pipeline ProgressSeptember 16, 2024 | markets.businessinsider.comTheravance Biopharma (NASDAQ:TBPH) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Theravance Biopharma in a report on Monday.September 16, 2024 | marketbeat.comSeth Klarman's Complete Exit from Theravance Biopharma IncSeptember 11, 2024 | finance.yahoo.comHere's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn SituationSeptember 6, 2024 | finance.yahoo.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Hold" by AnalystsTheravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) has received an average rating of "Hold" from the five brokerages that are currently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and two have given a buy recommendation to theAugust 31, 2024 | marketbeat.comZacks Research Brokers Lower Earnings Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH)Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Equities research analysts at Zacks Research dropped their Q3 2024 earnings per share estimates for shares of Theravance Biopharma in a research note issued on Monday, August 26th. Zacks Research analyst R. Department now anticipates that tAugust 28, 2024 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) to Post Q4 2025 Earnings of $0.41 Per Share, Zacks Research ForecastsTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Investment analysts at Zacks Research lifted their Q4 2025 earnings per share (EPS) estimates for shares of Theravance Biopharma in a note issued to investors on Monday, August 26th. Zacks Research analyst R. Department now expects that theAugust 27, 2024 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Stock Crosses Below Fifty Day Moving Average of $8.90Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Below 50 Day Moving Average of $8.90August 27, 2024 | marketbeat.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceAugust 27, 2024 | prnewswire.comSeth Klarman's Strategic Reduction in Theravance Biopharma IncAugust 15, 2024 | finance.yahoo.comVanguard Group Inc. Decreases Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Vanguard Group Inc. reduced its position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 23.0% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 2,685,853 shares of the biopharmaceutical company's stock after selling 803,409 shares during thAugust 11, 2024 | marketbeat.comNeed To Know: Analysts Just Made A Substantial Cut To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) EstimatesAugust 10, 2024 | finance.yahoo.comEli Samaha Buys 999,800 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) StockAugust 10, 2024 | insidertrades.comTheravance Biopharma (NASDAQ:TBPH) Rating Lowered to Hold at StockNews.comStockNews.com lowered shares of Theravance Biopharma from a "buy" rating to a "hold" rating in a report on Saturday.August 10, 2024 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Major Shareholder Eli Samaha Purchases 999,800 SharesTheravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) major shareholder Eli Samaha bought 999,800 shares of the business's stock in a transaction dated Wednesday, August 7th. The shares were acquired at an average cost of $7.80 per share, for a total transaction of $7,798,440.00. Following the transaction, the insider now directly owns 9,511,150 shares in the company, valued at approximately $74,186,970. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.August 9, 2024 | marketbeat.comSmall Cap Stocks: TBPH Stock Isn’t Ideal for Short Term InvestorsAugust 8, 2024 | msn.comTheravance Biopharma (NASDAQ:TBPH) Issues Earnings ResultsTheravance Biopharma (NASDAQ:TBPH - Get Free Report) announced its earnings results on Monday. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.25). The company had revenue of $14.26 million for the quarter, compared to analysts' expectations of $15.81 million. Theravance Biopharma had a negative net margin of 72.79% and a negative return on equity of 18.97%. During the same quarter in the prior year, the firm posted ($0.28) earnings per share.August 7, 2024 | marketbeat.comLeerink Partnrs Lowers Theravance Biopharma (NASDAQ:TBPH) to HoldLeerink Partnrs downgraded shares of Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a report on Tuesday.August 7, 2024 | marketbeat.comTheravance Biopharma: Hold Rating Maintained Amid Adjusted Sales Expectations and Development DelaysAugust 6, 2024 | markets.businessinsider.comLeerink Partners Downgrades Theravance Biopharma (TBPH)August 6, 2024 | msn.comTheravance Biopharma (NASDAQ:TBPH) Price Target Cut to $15.00 by Analysts at HC WainwrightHC Wainwright lowered their price target on shares of Theravance Biopharma from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Tuesday.August 6, 2024 | marketbeat.comTheravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | seekingalpha.comTheravance Biopharma Shares Dip to 52-Week Low After Wider-Than-Expected 2Q LossAugust 6, 2024 | marketwatch.comHold Rating on Theravance Biopharma Amidst Revised Revenue Projections and Pipeline DelaysAugust 6, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For Theravance BiopharmaAugust 6, 2024 | benzinga.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | msn.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the three brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and two haAugust 6, 2024 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Rating Lowered to Market Perform at SVB LeerinkSVB Leerink cut shares of Theravance Biopharma from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $15.00 to $10.00 in a research report on Tuesday.August 6, 2024 | marketbeat.comTheravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 5, 2024 | prnewswire.comTheravance Biopharma (NASDAQ:TBPH) Lowered to "Hold" at StockNews.comStockNews.com downgraded Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Thursday.August 1, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $5.01 Million Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)Jacobs Levy Equity Management Inc. increased its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 41.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 557,971 shares of the biopharmacJuly 31, 2024 | marketbeat.comTheravance Biopharma (TBPH) to Release Earnings on MondayTheravance Biopharma (NASDAQ:TBPH) will be releasing earnings after the market closes on Monday, August 5, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=237199)July 29, 2024 | marketbeat.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceJuly 25, 2024 | prnewswire.com Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Musk Says ‘Dollar Will Be Worth Nothing…’ (Ad)Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words… All you have to do is claim your free ticket to the event now… TBPH Media Mentions By Week TBPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TBPH News Sentiment▼1.000.41▲Average Medical News Sentiment TBPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TBPH Articles This Week▼12▲TBPH Articles Average Week Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANNX News HROW News KNSA News SNDX News RCKT News DVAX News RCUS News SPRY News EVO News TVTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TBPH) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
